Small Cell Lung Cancer Extensive Stage
GNPXGenprexCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for REQORSA (quaratusugene ozeplasmid) + Tecentriq in Small Cell Lung Cancer Extensive Stage. The expected timing is based on the latest available company guidance and may change.
Acclaim-3 trial. 1/2024- Open enrollment in DE portion. 11/18/25– Granted patent through 2037. Interim analysis after 25 patients in H1 2026. 02/10/26:- IP Australia patent intent; new University of Kentucky site; enroll 25 patients H1 2026, interim analysis H2 2026. 02/23/26:- Japan/EU patents for REQORSA+immunotherapy; Ph1 completed with no DLTs; Ph2 enrolling ~50; interim analysis H2 2026 after 25 patients. 03/18/26:- AACR 2026 posters present positive preclinical Reqorsa data, including biomarkers TROP2/PTEN and NK activation. 05/26/26:- ASCO 2026 biomarker data: 11 Acclaim-3 SCLC patients; Trop-2 low/non-evaluable; PTEN not linked to PFS.
Verification
Confirm timing and program details against the company announcement or filing.